Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction

Chaudhary, Ammar G.; Alreefi, Fadi; Aziz, Mohammad

doi:10.1016/j.cjco.2021.01.006

Cited by 3 publications

(2 citation statements)

References 59 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reducing heart rate to less than 70 bpm is related to a decrease in mortality and morbidity [ 6 ]. Ivabradine works on the I f channel and has been proven to reduce HFrEF hospitalization [ 6 , 43 ]. However, the optimization may be challenging in patients with CKD or with new increases in serum creatinine, hyperkalemia, and hypotension.…”

Section: Optimizing Medical Therapy In the Chronic Hfref Patientsmentioning

confidence: 99%

A Case-Based Implementation of Heart Failure Therapies, A Consensus Pathway by The Saudi Heart Failure Working Group

Bakhsh,

Jelaidan,

Chaudhary

et al. 2024

Journal of the Saudi Heart Association

View full text Add to dashboard Cite

The implementation of guideline-directed medical therapy (GDMT) in heart failure (HF) has many challenges in real-world clinical practice. The consensus document is written considering the variability of the clinical presentation of HF patients. HF medical therapies need frequent dose adjustment during hospital admission or when patients develop electrolyte imbalance, acute kidney injury, and other acute illnesses. The paper describes clinical scenarios and graphs that will aid the managing physicians in decision-making for HF therapy optimization.

show abstract

Section: Optimizing Medical Therapy In the Chronic Hfref Patientsmentioning

confidence: 99%

A Case-Based Implementation of Heart Failure Therapies, A Consensus Pathway by The Saudi Heart Failure Working Group

Bakhsh,

Jelaidan,

Chaudhary

et al. 2024

Journal of the Saudi Heart Association

View full text Add to dashboard Cite

show abstract

“…More recently, new drugs have been developed for the management of HFrEF, paving the way to new pathophysiological targets other than neurohormonal antagonism [27].…”

Section: Worsening Heart Failure: Is It Time To Adopt New Strategies ...mentioning

confidence: 99%

New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events

Lavalle,

Di Lullo,

Jabbour

et al. 2023

JCM

View full text Add to dashboard Cite

Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF) are prone to experience episodes of worsening symptoms and signs despite continued therapy, termed “worsening heart failure” (WHF). Despite guideline-directed medical therapy, worsening of chronic heart failure accounts for almost 50% of all hospital admissions for HF, and patients experiencing WHF carry a substantially higher risk of death and hospitalization than patients with “stable” HF. New drugs are emerging as arrows in the quiver for clinicians to address the residual risk of HF hospitalization and cardiovascular deaths in patients with WHF. This question-and-answer-based review will discuss the emerging definition of WHF in light of the recent clinical consensus released by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), the new therapeutic approaches to treat WHF and then move on to their timing and safety concerns (i.e., renal profile).

show abstract

Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?

Skouri¹,

Massih²,

Chaaban³

et al. 2023

WJCD

View full text Add to dashboard Cite

Heart failure (HF) is a clinical syndrome due to structural and/or functional cardiac anomalies, accompanied by elevated natriuretic peptide levels and/or cardiogenic pulmonary or systemic congestion; severely compromising patients' health, performance and quality of life. The advancement of novel treatment and their endorsement by international medical and scientific societies have shifted the treatment of HF with reduced ejection fraction (HFrEF) towards quadruple therapy: an angiotensin receptor-neprilysin inhibitor or an angiotensin-converting enzyme inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist and a sodium/glucose co-transporter-2 inhibitor (SGLT2i). This paper reviews the available literature on state-of-the-art diagnostic and therapeutic advances in HFrEF, discusses landmark trials that shifted the paradigm towards quadruple therapy in HFrEF, visits the potential challenges in Lebanon and globally, proposes an algorithm for treatment introduction and sequencing in HFrEF and highlights clinical considerations for HFrEF management and patient education and follow-up. This practical guidance could serve cardiologists and other medical specialists in identifying clinical signs of HFrEF, diagnosing patients, referring them or prescribing the components of quadruple therapy, and offering medical advice and follow-up. We highlight the role of SGLT2is in HF management and their effectiveness in reducing rates of hospitalization for HF as well as cardiovascular deaths, with satisfactory safety profile.

show abstract

Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction

Cited by 3 publications

References 59 publications

A Case-Based Implementation of Heart Failure Therapies, A Consensus Pathway by The Saudi Heart Failure Working Group

A Case-Based Implementation of Heart Failure Therapies, A Consensus Pathway by The Saudi Heart Failure Working Group

New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events

Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?

Contact Info

Product

Resources

About